Specialty Infusion Centers
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Specialty Infusion Centers - overview
Established
2017
Location
Brooklyn, NY, US
Primary Industry
Healthcare
About
Based in New York, US, and founded in 2017 by CEO Elan Katz, Specialty Infusion operates as a provider of ambulatory infusion and specialty pharmacy services for patients with chronic disease and complicated health conditions. In June 2023, Vivo Infusion, a portfolio company of InTandem Capital Partners, acquired Specialty Infusion Centers. Specialty Infusion provides therapies for patients such as Actemra, Adakveo, Amvuttra, Avsola, Benlysta, Briumvi, Fasenra, Fabrazyme, Givlaari, Intralipid, Leqvio, and many more. The company offers a wide range of Infusion and Injection Treatments such as Xenpozyme, Nexviazyme, Fasenra, Onpattro, Gammagard, Ultomiris, Ruxience, Truxima, and many more.
In addition, the firm serves locations including Braintree, Oburn, Bronx, Staten Island, New Paltz, and many others.
Current Investors
Vivo Infusion
Primary Industry
Healthcare
Sub Industries
Home Healthcare, Nursing Homes & Assisted Living, Clinics/Outpatient Services
Website
www.specialtyinfusion.com
Verticals
HealthTech
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Specialty Infusion Centers - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | Specialty Infusion Centers | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.